Is oestrogen an important player in melanoma progression?

Wspolczesna Onkologia

Volumn 18, Issue 5, 2014, Pages 302-306

  Janik, Marcelina E ^a   Belkot, Klaudyna ^a   Przybylo, Malgorzata ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

GPER; Melanoma; Oestrogen; Oestrogen receptor a; Oestrogen receptor

Indexed keywords

CYCLIC AMP; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN RECEPTOR; VERY LATE ACTIVATION ANTIGEN 5;

BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER GROWTH; CELL FUNCTION; DNA BINDING; ENDOMETRIUM CANCER; ESTROGEN RESPONSIVE ELEMENT; GENE CONTROL; HUMAN; LIGAND BINDING; MELANOMA; MELANOMA CELL; OVARY CANCER; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT;

EID: 84918794234     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.43938     Document Type: Review

References (75)

1. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
2. Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res 2004; 6: 39-52.
3. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane-bound estrogen receptor. J Endocrinol 2010; 204: 105- 14.
4. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307: 1625-30.
5. Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signal 2012; 24: 1515-21.
6. Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 2008; 29: 116-23.
7. Litwiniuk M, Brborowicz J. Estrogen receptor in breast cancer. Wspolczesna Onkol 2004; 8: 478-482.
8. Piekarski J. Estrogen and progesterone receptors in breast cancer - the current state of knowledge. Wspolczesna Onkol 2005; 9: 371-379.
9. Webb P, Nguyen P, Shinsako J, et al. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol Endocrinol 1998; 12: 1605-18.
10. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87: 905-31.
11. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 2005; 67: 335-76.
12. Kocanova S, Mazaheri M, Caze-Subra S, Bystricky K. Ligands specify estrogen receptor alpha nuclear localization and degradation. BMC Cell Biol 2010; 11: 98.
13. Dbska S, Potemski P. Structure and function of hormone receptors and their crosstalk with growth factor receptors. Wspolczesna Onkol 2010; 14: 347-354.
14. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag- Buck V, Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J 2000; 19: 4688-700.
15. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Structure 2003; 11: 741-6.
16. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005; 336: 1023-7.
17. Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and-negative human breast carcinomas. Anticancer Res 2008; 28 (1B): 479-83.
18. Rao J, Jiang X, Wang Y, Chen B. Advances in the understanding of the structure and function of ER-36, a novel variant of human estrogen receptor-alpha. J Steroid Biochem Mol Biol 2011; 127: 231-7.
19. Sandén C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Martensson UE, Olde B, Leeb-Lundberg LM. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol Pharmacol 2011; 79: 400-10.
20. Cheng SB, Graeber CT, Quinn JA, Filardo EJ. Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor- 30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 2011; 76: 892-6.
21. Otto C, Rohde-Schulz B, Schwarz G, et al. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008; 149: 4846-56.
22. Filardo EJ, Quinn JA, Bland KI, Frackelton Jr AR. Estrogen-induced activation of Erk-1 and Erk-2 requires the G-protein coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-60.
23. Maggiolini M, Vivacqua A, Fasanella G, et al. The G Protein-coupled receptor GPR30 mediates c-fos up-regulation by 17-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004; 279: 27008-16.
24. Prossnitz ER, Barton M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat 2009; 89: 89-97.
25. Li Y, Birnbaumer L, Teng CT. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1. Mol Endocrinol 2010; 24: 969-80.
26. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402(6764): 884-8.
27. Kanter-Lewensohn L, Girnita L, Girnita A, et al. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol 2000; 165: 131-7.
28. Quinn JA, Graeber CT, Frackelton AR Jr, Kim M, Schwarzbauer JE, Filardo EJ. Coordinate regulation of estrogen-mediated fibronectin matrix assembly and epidermal growth factor receptor transactivation by the G protein-coupled receptor, GPR30. Mol Endocrinol 2009; 23: 1052-64
29. De Marco P, Bartella V, Vivacqua A, et al. Insulin-like growth factor- I regulates GPER expression and function in cancer cells. Oncogene 2012; 32: 678-88.
30. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, Wang ZY. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010; 24: 709-21.
31. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004; 23: 6379-91.
32. Daryanani D, Plukker JT, De Hullu JA, Kuiper H, Nap RE, Hoekstra HJ. Pregnancy and early-stage melanoma. Cancer 2003; 97: 2248-53.
33. O'Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005; 103: 1217-26.
34. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol 2010; 28: 4038-44.
35. Mac Neil SM, Eves P, Richardson B, Molife R, Lorigan P, Wagner M, Layton C, Morandini R, Ghanem G. Oestrogenic steroids and melanoma cell interaction with adjacent skin cells influence invasion of melanoma cells in vitro. Pigment Cell Res 2000; 13 Suppl 8: 68-72.
36. Dobos J, Tímár J, Bocsi J, Burián Z, Nagy K, Barna G, Peták I, Ladá- nyi A. In vitro and in vivo antitumor effect of 2-methoxyestradiol on human melanoma. Int J Cancer 2004; 112: 771-6.
37. Regad T. Molecular and cellular pathogenesis of melanoma initiation and progression. Cell. Mol Life Sci 2013; 70: 4055-65.
38. Mohr P, Eggermont AMM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6): vi14-vi21.
39. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
40. Brenner S, Tamir E. Early detection of melanoma: the best strategy for a favorable prognosis. Clin Dermatol 2002; 20(3): 203-11.
41. Houghton AN, Polsky D. Focus on melanoma. Cancer Cell 2002; 2: 275-8.
42. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009; 20 (Suppl 6): vi1-vi7.
43. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86 (4): 172-8.
44. Ashley DJ. Sex differences in the incidence of tumours at various sites. Br J Cancer 1969; 23: 26-30.
45. Blois MS, Sagebiel RW, Abarbanel RM, Caldwell TM, Tuttle MS. Malignant melanoma of the skin. I. The association of tumor depth and type, and patient sex, age, and site with survival. Cancer 1983; 52: 1330-41.
46. Rampen FH. Sex differences in survival from cutaneous melanoma. Int J Dermatol 1984; 23: 444-52.
47. Reintgen DS, Paull DE, Seigler HF, Cox EB, McCarty KS Jr. Sex related survival differences in instances of melanoma. Surg Gynecol Obstet 1984; 159: 367-72.
48. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 1994; 129: 316-24.
49. Karakousis CP, Driscoll DL. Prognostic parameters in localised melanoma: gender versus anatomical location. Eur J Cancer 1995; 31A: 320-4.
50. Miller JG, Mac Neil S. Gender and cutaneous melanoma. Br J Dermatol 1997; 136: 657-65.
51. Kölmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilities and hazard functions of malignant melanoma in Germany 1972- 1996, an analysis of 10433 patients. Evolution of gender differences and malignancy. Eur J Cancer 2002; 38: 1388-94.
52. Hofmann MA, Coll SH, Küchler I, Kiecker F, Wurm R, Sterry W, Trefzer U. Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology 2007; 215: 10-6.
53. Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, Breuninger H, Garbe C. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008; 112: 1795-804.
54. O'Doherty CJ, Prescott RJ, White H, McIntyre M, Hunter JA. Sex differences in presentation of cutaneous malignant melanoma and in survival from stage I disease. Cancer 1986; 58: 788-92.
55. De Giorgi V, Gori A, Alfaioli B, Papi F, Grazzini M, Rossari S, Lotti T, Massi D. Influence of sex hormones on melanoma. J Clin Oncol 2011; 29: e94-e5.
56. Grill HJ, Benes P, Manz B, Schramm P, Morsches B, Korting GW, Pollow K. Steroid hormone receptors in human melanoma. Arch Dermatol Res 1982; 272: 97-101.
57. Creagan ET, Ingle JN, Woods JE, Pritchard DJ, Jiang NS. Estrogen receptors in patients with malignant melanoma. Cancer 1980; 46: 1785-6.
58. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008; 6: e003.
59. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor ? J Biol Chem 2010; 28: 39575-9.
60. Schmidt AN, Nanney LB, Boyd AS, King LE Jr, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol 2006; 15: 971-80.
61. De Giorgi V, Mavilia C, Massi D, et al. Estrogen receptor expression in cutaneous melanoma a real-time reverse transcriptase - polymerase chain reaction and immunohistochemical study. Arch Dermatol 2009; 145: 30-6.
62. De Giorgi V, Gori A, Gandini S, et al. Estrogen receptor beta and melanoma. A comparative study. Br J Dermatol 2013; 168: 513-519.
63. Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol 2008; 35: 215-21.
64. Grin CM, Driscoll MS, Grant-Kels JM. The relationship of pregnancy, hormones, and melanoma. Semin Cutan Med Surg 1998; 17: 167-71.
65. Asendrych A, Deptaa A. Hormonal replacement therapy in hormone- dependent cancers. Wspolczesna Onkol 2004; 8:81-85.
66. Nading MA, Nanney LB, Boyd AS, Ellis DL. Estrogen receptor - expression in nevi during pregnancy. Exp Dermatol 2008; 17: 489-97.
67. Nading MA, Nanney LB, Ellis DL. Pregnancy and estrogen receptor - expression in a large congenital nevus. Arch Dermatol 2009; 145: 691-4.
68. Koomen ER, Joosse A, Herings RMC, Casparie MlK, Guchelaar HJ, Nijsten T. Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. Melanoma Res 2009; 19: 327-32.
69. Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011; 103: 1469-75.
70. De Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma. Crit Rev Oncol Hematol 2003; 47: 35-63.
71. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011; 47: 2150-7.
72. Spagnolo F, Queirolo P. Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 2012; 304: 177-84.
73. Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med 2012; 5: 139-48.
74. Scheier B, Amaria R, Lewis K, Gonzalez R. Novel therapies in melanoma. Immunotherapy 2011; 3: 1461-9.
75. Mackiewicz J, Kwinta A. New targeted therapies in the treatment of patients with metastatic melanoma. Wspolczesna Onkol 2010; 14: 15-22.